<DOC>
	<DOC>NCT00000326</DOC>
	<brief_summary>The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective alternate day dosing regimen.</brief_summary>
	<brief_title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1</brief_title>
	<detailed_description>Alternate-day dosing with the 8mg buprenorphine-naloxone tablet is as safe and effective as daily dosing. Outcomes are improved when the total weekly dose provided during alternate-day dosing is equal to that given during daily dosing.</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<mesh_term>Heroin</mesh_term>
	<criteria>Individuals must be currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Comorbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency. Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSMIV) Axis I psychiatric disorder (e.g. psychosis, manicdepressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Heroin Dependence</keyword>
</DOC>